Data from real-world studies in patients with IPF support the safety profile of nintedanib observed in clinical trials.

The most common adverse events associated with nintedanib in real-world studies were diarrhoea, nausea and vomiting, which infrequently led to treatment discontinuation.

Liver enzymes should be monitored in patients treated with nintedanib.

Nintedanib dose adjustments, treatment interruptions and anti-diarrhoeal medications are frequently employed to manage adverse events.

Effective management of the adverse events associated with nintedanib in clinical practice is important to minimise their impact and help patients remain on therapy.